Robert MD - Jazz Pharmaceuticals Ex RD

J7Z Stock  EUR 118.85  2.00  1.71%   

Insider

Robert MD is Ex RD of Jazz Pharmaceuticals plc
Age 56
Phone353 1 634 7800
Webhttps://www.jazzpharma.com

Jazz Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of 0.053 % which means that it generated a profit of $0.053 on every $100 spent on assets. This is way below average. Jazz Pharmaceuticals' management efficiency ratios could be used to measure how well Jazz Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.
Jazz Pharmaceuticals plc has accumulated 6.02 B in total debt with debt to equity ratio (D/E) of 64.5, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Jazz Pharmaceuticals plc has a current ratio of 3.09, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Jazz Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Jazz Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Jazz Pharmaceuticals plc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Jazz to invest in growth at high rates of return. When we think about Jazz Pharmaceuticals' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Ola KalleniusMercedes Benz Group AG
54
Harald WilhelmMercedes Benz Group AG
57
Camilla SylvestNovo Nordisk AS
51
Sylke MaasBioNTech SE
N/A
Kristen AmbroseVertex Pharmaceuticals Incorpor
46
Tracey FranklinModerna
39
Juan AndresModerna
58
Steffen HoffmannMercedes Benz Group AG
53
Lars JorgensenNovo Nordisk AS
57
Henrik WulffNovo Nordisk AS
53
Hubertus TroskaMercedes Benz Group AG
63
Sean MarettBioNTech SE
58
Damian EsqVertex Pharmaceuticals Incorpor
47
Jorg BurzerMercedes Benz Group AG
53
Maziar DoustdarNovo Nordisk AS
53
Stephen HogeModerna
42
Markus SchaferMercedes Benz Group AG
58
Shannon KlingerModerna
52
Lavina CFAModerna
N/A
Karsten KnudsenNovo Nordisk AS
52
MD FASNVertex Pharmaceuticals Incorpor
50
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. Jazz Pharmaceuticals plc has licensing and collaboration agreements with ImmunoGen, Inc. Codiak BioSciences, Inc. Pfenex, Inc. and XL-protein GmbH. JAZZ PHARMACEUT operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 1460 people. Jazz Pharmaceuticals plc (J7Z) is traded on Frankfurt Exchange in Germany and employs 3,200 people.

Management Performance

Jazz Pharmaceuticals plc Leadership Team

Elected by the shareholders, the Jazz Pharmaceuticals' board of directors comprises two types of representatives: Jazz Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Jazz. The board's role is to monitor Jazz Pharmaceuticals' management team and ensure that shareholders' interests are well served. Jazz Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Jazz Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Robert MD, Ex RD
Finbar Larkin, VP Operations
George Eliades, Sr Officer
Daniel Swisher, President COO
Patricia Carr, VP Officer
Heidi Manna, VP Officer
Neena JD, Ex Officer
Renee Gala, Ex CFO
Andrea Flynn, VP Relations
Bruce Cozadd, Chairman of the Board, CEO

Jazz Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Jazz Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Additional Information and Resources on Investing in Jazz Stock

When determining whether Jazz Pharmaceuticals plc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Jazz Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Jazz Pharmaceuticals Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Jazz Pharmaceuticals Plc Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jazz Pharmaceuticals plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Please note, there is a significant difference between Jazz Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Jazz Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Jazz Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.